Home › Venous Thromboembolism › NCT04295486

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism (VTE) Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial.

Who can join

Ages 19 and older · All sexes

Inclusion criteria:

* \> 18 years of age
* Planning to undergo a primary total hip or knee arthroplasty

Exclusion Criteria:

* High risk patients for VTE as defined by:

  * History of venous thromboembolism
  * Active malignancy
  * Known pro thrombotic condition
* BMI \> 40
* Patients requiring anticoagulation for pre-existing conditions
* Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others.
* Patients not fluent in the language of the informed consent form
* Prisoners
* Pregnancy
* Reported to have mental illness or belonging to a vulnerable population

About the study

This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.

What is being tested

• Aspirin (drug)

Sponsor: University of Miami · Participants: 5,478 · Started: Mar 1, 2021

Contact the study team

• Ramakanth Yakkanti, MD · Phone: 502-689-3127

Official record on ClinicalTrials.gov — NCT04295486

Locations in the U.S.

Conditions

• Venous Thromboembolism

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.